Non Hodgkin's Lymphoma Clinical Trial
Official title:
A Multiple Center Study on NOXA Expression-guided Randomized Chidamide Bridging Intervention in CAR-T Treated NHL Patients
The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of CAR-T cells. This study will enroll approximately 120 subjects with recurrent or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Those with high expression of NOXA will receive conventional CAR-T treatment (without chidamide bridging), and those with low expression of NOXA will be randomly assigned 1:1 to those without or containing chidamide bridging. The purpose of this study was to evaluate the clinical response and safety of chidamide bridging.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age 16-75, male or female; 2. Recurrent or refractory large B-cell lymphoma (LBCL) ,grade 1-3a follicular lymphoma (FL) and mantle cell lymphoma (MCL). Recurrent or refractory disease was defined as progression after systemic treatment with second-line or more lines (including CD20 monoclonal antibody and doxorubicin) or primary resistance (disease progression during first-line treatment or within 6 months after completion of treatment). LBCL includes diffuse large B-cell lymphoma non-specific type (DLBCL-NOS), diffuse large B-cell lymphoma transformed by follicular lymphoma (TFL), grade 3b FL, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma with MYC and Bcl-2 and/or Bcl-6 rearrangement ( double strike/triple hit lymphoma, DHL/THL); 3. Eastern Cooperative Oncology Group (ECOG) physical status is 0-3; 4. Life expectancy =12 weeks; 5. Subjects must be willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide lymph node or tissue biopsy from the most recent available archived tissue for immunohistochemical NOXA testing and pathology review in the study center laboratory; 6. There are measurable target lesions; 7. CD19 positive; 8. Are willing to use contraception according to the following criteria: A. Women of reproductive age (15-49 years) must undergo a pregnancy test with negative results within 7 days before starting treatment; B. Women of reproductive age should use effective contraception for at least 120 days after the last dose of the study drug (contraceptive success rate of at least 99%). The subject should communicate with the available contraceptive methods with at least 99% success rate and confirm the understanding of the period; C. Male subjects used effective contraception for at least 93 days after the last dose of study drug (contraceptive success rate of at least 99%). The subject should communicate with the available contraceptive methods with at least 99% success rate and confirm the understanding of the period; D. Infertile women (i.e., surgically sterilized by hysterectomy and/or bilateral oophorectomy or amenorrhea =12 months and age > 45 years) are not subject to conditions A and B above 9. Adequate bone marrow and organ functions (normal values shall not be obtained with growth factors, and hemocytopenia caused by lymphoma invasion of bone marrow is not subject to conditions A, B, and C below) : A. Neutrophil count (ANC) =1.0×10^9/L; B. Hemoglobin =8.0g/dL; C. Platelet count =50×10^9/L; D. Total bilirubin =1.5× upper limit of normal value (ULN) (< 3 TIMES ULN for patients with Gilbert syndrome, cholestasis caused by hilar compression adenosis, biliary obstruction caused by liver involvement or lymphoma); E. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) =2.5×ULN or =5×ULN when liver invasion is present; F. Creatinine clearance =40ml/min using the cockcroft-gault equation or glomerular filtration rate =40ml/min/1.73m2 using the modified renal disease diet formula; G. Lipase =1.5×ULN. Exclusion Criteria: 1. Patients known to be allergic to the drug Chidamide; 2. Lymphoma involves the central nervous system; 3. Known human immunodeficiency virus (HIV) infection or immunopositive test; 4. Viral infections that cannot be controlled by antiviral drugs, such as herpetic virus infection, acute or chronic active hepatitis B, acute or chronic active hepatitis C, etc. [Note: chronic hepatitis B virus (HBV) carriers or non-active hepatitis B surface antigen (HBsAg) positive subjects and HBV-DNA lower than the detection limit can be included in the group; hepatitis C virus (HCV) antibody negative can be enrolled, HCV antibody positive patients need to be tested for HCV-RNA, if negative can be enrolled]; 5. Presence of active infectious disease requiring treatment; 6. Received live vaccine within 30 days prior to enrollment; 7. Active autoimmune disease requiring systemic treatment within 12 months prior to enrollment (i.e., disease-modifying drugs, corticosteroids, or immunosuppressive drugs). Note: Alternative therapies (such as thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary dysfunction) are not considered a systemic treatment; 8. History of severe allergic reactions; 9. Presence of congestive heart failure or uncontrolled arrhythmias classified by the New York Heart Association as class III-IV; 10. Patients with clinically significant electrocardiogram abnormalities and potential risk of malignant arrhythmias; 11. Clinically significant cardiac events, including unstable angina, acute myocardial infarction, and/or cardiac transmission problems, occurred within 6 months prior to enrollment; 12. A history of stroke or intracranial hemorrhage within 3 months prior to enrollment; 13. Major surgery or trauma occurred within 28 days prior to enrollment, or major side effects have not been recovered; 14. Accompanied by uncontrolled major medical conditions, including, but not limited to, kidney, liver, blood, gastrointestinal, endocrine, pulmonary, neurological, brain or psychiatric disorders; 15. Current or previous malignancy within 3 years prior to enrollment, excluding cured basal or squamous cell skin cancer, superficial bladder cancer, prostatic intraepithelial tumor and carcinoma in situ of the cervix; 16. Conditions in which a known mental or physical illness interferes with cooperation with the requirements of the study or disrupts the results or interpretation of the results and, in the opinion of the therapeutic investigator, makes the patient unfit for study participation; 17. There is the situation that the researcher's judgment will interfere with the whole study participation; Situations where there is significant risk to the subject; Or interferes with the interpretation of research data; 18. Pregnant or breast-feeding patients; 19. Inability to swallow and retain oral medications, malabsorption syndrome, diseases that significantly affect gastrointestinal function, total resection of the stomach or small intestine, ulcerative colitis, symptomatic inflammatory bowel disease, partial or complete intestinal obstruction; 20. Inability to understand or unwillingness to sign informed consent. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tongren Hospital, Capital Medical University | Beijing | Beijing |
China | Biotherapeutic Department, Chinese PLA General Hospital | Beijing | |
China | Peking Union Medical College Hospital | Beijing | Beijing |
China | Peking University Cancer Hospital | Beijing | Beijing |
China | West China Hospital of Sichuan University | Chengdu | Sichuan |
China | Sun Yat-Sen University Cancer Hospital | Guangzhou | Guangzhou |
China | Zhujiang Hospital of Southern Medical University | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Zhejiang University | Hangzhou | Zhejiang |
China | Tongji Hospital of Tongji University | Shanghai | Shanghai |
China | The First Affiliated Hospital of Soochow University | Suzhou | Suzhou |
China | Tianjin Medical University Cancer Institute and Hospital | Tianjin | Tianjin |
China | Tongji Hospital, Tongji Medical College of HUST | Wuhan | Hubei |
China | Xiehe Hospital, Tongji Medical College of HUST | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Chinese PLA General Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Effect of chidamide intervention on NOXA expression | For the group with low NOXA expression, a secondary biopsy was performed at the same site to detect changes in NOXA expression before CAR-T infusion. In the chidamide bridging group, the timing of secondary biopsy was arranged at least 6 times' chidamide therapy and before CAR-T infusion. | an average of 4 weeks | |
Primary | Percentage of participants with progression-free survival (PFS) at 6 months after CAR-T infusion among all participants | PFS is defined as the time between the date of CAR-T infusion and disease progression or death from any cause. At the time of statistical analysis of study endpoints, there were no PFS events, and data were truncated as the date of the last objective tumor evaluation. Patients who were lost to follow-up or withdrew informed consent will be included in the end point evaluation, with data truncated as the date of the last objective tumor evaluation. | 6 months | |
Secondary | Incidence of adverse events (AE) of chidamide bridging and subsequent CAR-T infusion arm | AE is defined as any adverse medical event from the time between the date of randomization and the date of 12 months after CAR-T infusion. AE may be an adverse sign (including abnormal laboratory tests, etc.), symptom, or illness that is not related to the purpose of medication and is time-related to drug use, regardless of causality to the drug, such as long-term cytopenia, cytokine release syndrome, neurotoxicity, etc. | 12 months | |
Secondary | Participants with objective response rate (ORR) at 3 months after CAR-T infusion among all participants | ORR was defined as the percentage of subjects who achieved complete response or partial response assessed by investigators and based on the Lugano 2014 assessment criterion. All subjects who do not meet objective response criteria by the data analysis deadline will be considered nonresponders. The source of this endpoint will only include the assessment of response obtained after CAR-T infusion and prior to any additional antitumor therapy. | 3 months | |
Secondary | Participants with complete response rate (CRR) at 3 months after CAR-T infusion among all participants | CRR was defined as the percentage of subjects who achieved a CR assessed by investigators and based on the Lugano 2014 assessment criterion. | 3 months | |
Secondary | Percentage of participants with recurrence-free survival (RFS) at 6 months after CAR-T infusion among all participants | RFS was defined as the time between the date of CAR-T infusion and the date of first lymphoma recurrence (local, regional, distant metastasis) or death (whatever the cause) for subjects who received complete response after CAR-T infusion. For participants who remained alive and whose disease had not recurred, RFS was censored on the date of last visit/contact with disease assessments. | 6 months | |
Secondary | Percentage of participants with RFS at 12 months after CAR-T infusion among all participants | RFS was defined as above. | 12 months | |
Secondary | Percentage of participants with PFS at 12 months after CAR-T infusion among all participants | PFS was defined as above. | 12 months | |
Secondary | Percentage of participants with overall survival (OS) at 12 months after CAR-T infusion among all participants | OS was defined as the time between the date of CAR-T infusion and death from any cause. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06014073 -
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
Terminated |
NCT00909948 -
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
Recruiting |
NCT06285422 -
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
|
Phase 1 | |
Withdrawn |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
Completed |
NCT00477945 -
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
|
Phase 1 | |
Terminated |
NCT00038818 -
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT01789723 -
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
|
Phase 1 | |
Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
Terminated |
NCT00714259 -
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
|
Phase 2/Phase 3 | |
Completed |
NCT01018758 -
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
|
Phase 2 | |
Completed |
NCT00001830 -
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
|
Phase 1 | |
Recruiting |
NCT01063439 -
BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)
|
Phase 2 | |
Completed |
NCT01527422 -
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
|
Phase 1/Phase 2 | |
Completed |
NCT00834951 -
Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04497688 -
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
|
N/A | |
Completed |
NCT00597714 -
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT00001430 -
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
|
Phase 2 |